CORT vs KRYS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CORT · Corcept Therapeutics$72.77 ▲ 1.59%
KRYS · Krystal Biotech$300.88 ▲ 0.21%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CORT -3.6%
- KRYS +50.8%
Head to head
| Metric | CORT | KRYS |
|---|---|---|
| Price | $72.77 | $300.88 |
| Change today | ▲ 1.59% | ▲ 0.21% |
| Market cap | $7.96B | $8.92B |
| Return, 3 months | -36.3% | -9.3% |
| Return, year to date | +109.1% | +22.0% |
| Return, 1 year | -1.3% | +52.0% |
| P/E (TTM) | 54.7 | 40.9 |
| P/B | 9.6 | 6.2 |
| P/E percentile vs own 5y | 74th | 69th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +31.7% | +24.1% |
| Net profit growth (YoY) | +22.3% | +42.9% |
| Gross margin | 98.3% | 94.6% |
| Operating margin | 0.8% | 44.9% |
| Net margin | 6.5% | 54.8% |
| Return on equity | 8.1% | 20.1% |
| Analyst target vs. price | +127.8% | +34.1% |
| Analyst buy share | 100% | 88% |
| RSI (14) | 22 | 40 |
| 30-day volatility | 79.8% | 46.7% |
| Max drawdown, 1 year | -63.5% | -21.8% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- KRYS is the largest of the group by market value.
- KRYS has returned the most over the past year.
- KRYS carries the lowest trailing P/E.
- CORT is growing revenue fastest.
- KRYS keeps the most profit per dollar of sales.
- KRYS has been the calmest stock over the last 30 days.